Sansure Biotech Inc.

SHSE:688289 Stock Report

Market Cap: CN¥11.6b

Sansure Biotech Future Growth

Future criteria checks 5/6

Sansure Biotech is forecast to grow earnings and revenue by 36.5% and 26.6% per annum respectively. EPS is expected to grow by 36.4% per annum. Return on equity is forecast to be 6.5% in 3 years.

Key information

36.5%

Earnings growth rate

36.4%

EPS growth rate

Medical Equipment earnings growth25.8%
Revenue growth rate26.6%
Future return on equity6.5%
Analyst coverage

Low

Last updated15 Jan 2025

Recent future growth updates

Recent updates

Some Confidence Is Lacking In Sansure Biotech Inc.'s (SHSE:688289) P/E

Jan 08
Some Confidence Is Lacking In Sansure Biotech Inc.'s (SHSE:688289) P/E

Sansure Biotech's (SHSE:688289) Problems Go Beyond Weak Profit

Nov 03
Sansure Biotech's (SHSE:688289) Problems Go Beyond Weak Profit

Sansure Biotech Inc.'s (SHSE:688289) 39% Price Boost Is Out Of Tune With Earnings

Oct 09
Sansure Biotech Inc.'s (SHSE:688289) 39% Price Boost Is Out Of Tune With Earnings

Sansure Biotech (SHSE:688289) Could Be Struggling To Allocate Capital

Oct 03
Sansure Biotech (SHSE:688289) Could Be Struggling To Allocate Capital

Is Sansure Biotech (SHSE:688289) A Risky Investment?

Sep 12
Is Sansure Biotech (SHSE:688289) A Risky Investment?

Sansure Biotech Inc. (SHSE:688289) Investors Are Less Pessimistic Than Expected

Aug 21
Sansure Biotech Inc. (SHSE:688289) Investors Are Less Pessimistic Than Expected

Sansure Biotech (SHSE:688289) May Have Issues Allocating Its Capital

Jun 03
Sansure Biotech (SHSE:688289) May Have Issues Allocating Its Capital

Why Sansure Biotech's (SHSE:688289) Soft Earnings Are Just The Beginning Of Its Problems

May 03
Why Sansure Biotech's (SHSE:688289) Soft Earnings Are Just The Beginning Of Its Problems

Sansure Biotech Inc.'s (SHSE:688289) Business Is Trailing The Industry But Its Shares Aren't

Apr 26
Sansure Biotech Inc.'s (SHSE:688289) Business Is Trailing The Industry But Its Shares Aren't

Sansure Biotech's (SHSE:688289) Returns On Capital Are Heading Higher

Feb 28
Sansure Biotech's (SHSE:688289) Returns On Capital Are Heading Higher

Earnings and Revenue Growth Forecasts

SHSE:688289 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20262,504575N/A3872
12/31/20252,016406N/A2793
12/31/20241,497279N/A543
9/30/20241,407259-150203N/A
6/30/20241,296429-23697N/A
3/31/20241,203385-29936N/A
12/31/20231,007364-34844N/A
9/30/20233,0156386171,161N/A
6/30/20234,1889049731,523N/A
3/31/20235,2061,3451,3871,890N/A
12/31/20226,4501,9372,0002,559N/A
9/30/20225,3162,0841,2551,673N/A
6/30/20225,1762,2471,5511,963N/A
3/31/20224,7912,2721,6332,121N/A
12/31/20214,5152,2431,5041,877N/A
9/30/20214,4252,3612,0502,316N/A
6/30/20214,6912,5062,1752,404N/A
3/31/20215,5263,0462,6682,801N/A
12/31/20204,7632,6172,5342,642N/A
9/30/20203,7272,0341,7811,830N/A
6/30/20202,2991,2631,0971,150N/A
3/31/2020683233170203N/A
12/31/201936539-1222N/A
12/31/20183037-2310N/A
12/31/2017225-11N/A-61N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 688289's forecast earnings growth (36.5% per year) is above the savings rate (2.8%).

Earnings vs Market: 688289's earnings (36.5% per year) are forecast to grow faster than the CN market (25% per year).

High Growth Earnings: 688289's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 688289's revenue (26.6% per year) is forecast to grow faster than the CN market (13.3% per year).

High Growth Revenue: 688289's revenue (26.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 688289's Return on Equity is forecast to be low in 3 years time (6.5%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/01 20:17
End of Day Share Price 2025/01/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sansure Biotech Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Shiyu ChenChina International Capital Corporation Limited
Zhu ChenCitic Securities Co., Ltd.
Shuo SongCitic Securities Co., Ltd.